Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic peptide from C-terminus of the precursor form of the mouse Flk-1|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50|
|Western Blot (WB)||5-10 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-16487 targets Flk-1 in IHC (P) and WB applications and shows reactivity with mouse, Rat, and Human samples.
The PA5-16487 immunogen is a synthetic peptide from C-terminus of the precursor form of the mouse Flk-1.
Flk-1/KDR vascular endothelial growth factor receptor 2, a cell membrane receptor kinase, is a high affinity receptor for vascular endothelial growth factor and is putatively involved in the growth of endothelial cells and angiogenesis. It contains seven immunoglobulin like sequences in the extracellular domain and exhibits sequence similarity to Flt-1 and Flt-4.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression.
PA5-16487 was used in immunohistochemistry - paraffin section and western blot to characterize the prognostic role of myoferlin expression in non-small cell lung cancer in correlation with VEGFR-2 expression
|Song DH,Ko GH,Lee JH,Lee JS,Lee GW,Kim HC,Yang JW,Heo RW,Roh GS,Han SY,Kim DC||Oncology letters (11:998)||2016|
Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma.
PA5-16487 was used in immunohistochemistry to study the prognostic and therapeutic value of the immunohistochemical expression of VEGF-A, VEGFR2 and VEGFR3 in patients with endometrial carcinoma
|Wang J,Taylor A,Showeil R,Trivedi P,Horimoto Y,Bagwan I,Ewington L,Lam EW,El-Bahrawy MA||Cytokine (68:94)||2014|
6130401C07; CD309; Fetal liver kinase 1; fetal liver kinase-1; FLK-1; Flk1; FLK1 kinase insert domain receptor (a type III receptor tyrosine kinase) (VEGF receptor 2); FLK1 kinase insert domain receptor (VEGF receptor 2); KDR; kinase insert domain protein receptor; Kinase insert domain receptor; kinase insert domain receptor (a type III receptor tyrosine kinase); kinase NYK; Krd-1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble vascular endothelial growth factor receptor 2; soluble VEGFR2; sVEGFR-2; tyrosine kinase growth factor receptor; Vascular endothelial growth factor receptor 2; vascular endothelial growth factor receptor- 2; vascular endothelial growth factor receptor-2; vascular endothelial growth factor receptor-3; VEGF receptor-2; VEGFR-2; VEGFR2
6130401C07; CD309; Flk-1; FLK1; KDR; Krd-1; Ly73; sVEGFR-2; VEGFR; VEGFR-2; VEGFR2